Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats.
The calcium antagonist flunarizine (FLN) was tested for its ability to prevent doxorubicin (DXR)-induced cardiotoxicity in the rat. A cumulative dose of 9.0 mg/kg of DXR was administered i.v. over a period of 1 week. FLN (10 mg/kg/day i.p., 6 days/week) was administered according to two different time schedules, covering respectively the first and last 4 weeks after the beginning of DXR treatment. The two schedules were adopted to assess whether early and/or delayed DXR-induced cardiotoxic effects were affected by FLN. The development of cardiac toxicity was monitored by ECG recordings. The animals were sacrificed 8 weeks after the beginning of DXR treatment. The contractile performance of isolated atria and the morphological pattern of left ventricular fragments were subsequently evaluated. The early administration schedule of FLN was shown to be ineffective in preventing DXR-induced cardiotoxicity and in some cases was actually found to potentiate the effects of DXR. In contrast, the histological evaluation of ventricular preparations from rats treated with DXR and FLN according to the delayed time schedule showed a significant improvement with respect to hearts from animals treated with DXR alone. An inhibition of the delayed calcium overload occurring after DXR administration has been proposed as a possible mechanism for this protective action.
Villani
F
F
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano.
Galimberti
M
M
Monti
E
E
Piccinini
F
F
Poggi
P
P
Lanza
E
E
Rozza
A
A
Favalli
L
L
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D004317:Doxorubicin / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D004334:Drug Administration Schedule; D004562:Electrocardiography; D005260:Female; D005444:Flunarizine / Q000008:administration & dosage / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects*; D066298:In Vitro Techniques; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000473:pathology; D051381:Rats; D011919:Rats, Inbred Strains
D002121:Calcium Channel Blockers; D004317:Doxorubicin; D005444:Flunarizine